mirabegron

Phase 3Active

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Neurogenic Detrusor Overactivity

Conditions

Neurogenic Detrusor Overactivity

Trial Timeline

Feb 28, 2024 → Sep 30, 2026

NCT ID

NCT05621616

About mirabegron

mirabegron is a phase 3 stage product being developed by Astellas Pharma for Neurogenic Detrusor Overactivity. The current trial status is active. This product is registered under clinical trial identifier NCT05621616. Target conditions include Neurogenic Detrusor Overactivity.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05621616	Phase 3	Active	Feb 28, 2024	Sep 30, 2026	Neurogenic Detrusor Overactivity
NCT04562090	Approved	Completed	Jan 6, 2021	Mar 30, 2022	Urge Incontinence
NCT04501640	Approved	Completed	Sep 21, 2020	Oct 27, 2020	Pharmacokinetics of Mirabegron
NCT02981459	Approved	Withdrawn	Dec 8, 2017	Jun 1, 2018	Urinary Frequency/Urgency
NCT02916693	Phase 1/2	Completed	Aug 1, 2017	Jan 1, 2020	Erectile Dysfunction
NCT02751931	Phase 3	Completed	Jun 17, 2016	May 6, 2019	Neurogenic Detrusor Overactivity
NCT02526979	Phase 1	Completed	Dec 17, 2015	Sep 30, 2016	Overactive Bladder
NCT02495389	Approved	Completed	Jan 28, 2015	Jan 29, 2019	Overactive Bladder
NCT02211846	Phase 1	Completed	Sep 21, 2014	Sep 21, 2015	Neurogenic Detrusor Overactivity
NCT01898624	Pre-clinical	Completed	Dec 4, 2012	Jan 10, 2018	Overactive Bladder
NCT02570035	Pre-clinical	Completed	Dec 1, 2012	Mar 1, 2015	Overactive Bladder
NCT00939757	Phase 1	Completed	May 1, 2009	Jul 1, 2009	Healthy
NCT01285596	Phase 1	Completed	Mar 1, 2009	Nov 1, 2009	Healthy Volunteers
NCT01579461	Phase 1	Completed	Nov 1, 2008	Apr 1, 2009	Pharmacokinetics

Competing Products

20 competing products in Neurogenic Detrusor Overactivity

See all competitors

Product	Company	Stage	Hype Score
Mirabegron	Astellas Pharma	Phase 3	77
Solifenacin succinate	Astellas Pharma	Phase 3	77
Solifenacin succinate	Astellas Pharma	Phase 3	77
Mirabegron	Astellas Pharma	Phase 1	33
SAF312 + Placebo to SAF312	Novartis	Phase 2	52
4 mg Fesoterodine ER tablet from Zwickau + 4 mg fesoterodine ER tablet from Freiburg + 8 mg fesoterodine ER tablet from Zwickau + 8 mg fesoterodine ER tablet from Freiburg	Pfizer	Phase 1	32
Fesoterodine PR 4 mg + Fesoterodine PR 8 mg + Fesoterodine BIC 2 mg + Fesoterodine BIC 4 mg	Pfizer	Phase 3	76
Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B) + Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B) + Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B) + Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A) + Fesoterodine BIC SR4 fed (Treatment E in Part B)	Pfizer	Phase 1	32
Fesoterodine PR 4 mg + Fesoterodine PR 8 mg + Fesoterodine PR 8 mg + Oxybutynin + Fesoterodine PR + Fesoterodine BIC 2 mg + Fesoterodine BIC 4 mg	Pfizer	Phase 3	76
alfuzosin (SL770499)	Sanofi	Phase 3	76
Alfuzosin + Placebo	Sanofi	Phase 3	76
Droxidopa capsules + Placebo capsules	Lundbeck	Approved	82
Rec 0/0438 1 mg or Rec 0/0438 2 mg + placebo	Recordati	Phase 1/2	38
Ampreloxetine + Placebo	Theravance Biopharma	Phase 3	72
ampreloxetine + Placebo	Theravance Biopharma	Phase 3	72
ampreloxetine + Placebo	Theravance Biopharma	Phase 3	72
TD-9855 + Placebo	Theravance Biopharma	Phase 2	47
ampreloxetine	Theravance Biopharma	Phase 3	72
Ampreloxetine <Dose A> + Ampreloxetine <Dose B> + Ampreloxetine Placebo + Moxifloxacin + Moxifloxacin Placebo	Theravance Biopharma	Phase 1	28
Ampreloxetine	Theravance Biopharma	Phase 1	28

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved